Novel targets for tuberculosis drug discovery

Current Opinion in Pharmacology

Volumn 6, Issue 5, 2006, Pages 459-467

  Mdluli, Khisimuzi ^a   Spigelman, Melvin ^a  

^a GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 3 NITROPROPIONIC ACID; 4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; ADENOSINE TRIPHOSPHATE; ALANINE RACEMASE; ARABINOGALACTAN; CYCLOSERINE; DEXTRO ALANINE DEXTRO ALANINE LIGASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETHAMBUTOL; ETHIONAMIDE; FOSMIDOMYCIN; GLYOXYLIC ACID; ISONIAZID; LEUCINE; MALATE SYNTHASE; MENAQUINONE; METHOTREXATE; MYCOLIC ACID; PEPTIDOGLYCAN; PHOSPHORIBOSYLTRANSFERASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; REGULATOR PROTEIN; RIBONUCLEOTIDE REDUCTASE; S ADENOSYLMETHIONINE; SHIKIMIC ACID; THIOLACTOMYCIN; TRIMETHOPRIM; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

AMINO ACID SYNTHESIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BACTERIAL GENOME; CARBOHYDRATE SYNTHESIS; DNA SYNTHESIS; DRUG DESIGN; DRUG RESEARCH; DRUG SENSITIVITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; TREATMENT DURATION; TUBERCULOSIS;

AMINO ACIDS; ANTITUBERCULAR AGENTS; CELL WALL; DNA, BACTERIAL; DRUG DESIGN; FATTY ACIDS; GALACTANS; ISOCITRATE LYASE; PEPTIDOGLYCAN;

EID: 33748419613     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.06.004     Document Type: Review

References (84)

1. Dye C., Garnett G.P., Sleeman K., and Williams B.G. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 352 (1998) 1886-1891
2. World Health Organization: Fact Sheet No 104: tuberculosis. WHO Fact Sheets. Geneva: WHO; 2002.
3. Bloom B.R. Tuberculosis: Pathogenesis, Protection, and Control (1994), American Society for Microbiology Press, Washington, DC
4. LeMagueres P., Im H., Ebalunode J., Strych U., Benedik M.J., Briggs J.M., Kohn H., and Krause K.L. The 1.9 A crystal structure of alanine racemase from Mycobacterium tuberculosis contains a conserved entryway into the active site. Biochemistry 44 (2005) 1471-1481
5. Belanger A.E., Besra G.S., Ford M.E., Mikusova K., Belisle J.T., Brennan P.J., and Inamine J.M. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in the cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA 93 (1996) 11919-11924
6. Escuyer V.E., Lety M.A., Torrelles J.B., Khoo K.H., Tang J.B., Rithner C.D., Frehel C., McNeil M.R., Brennan P.J., and Chatterjee D. The role of the embA and embB gene products in the biosynthesis of the terminal hexaarabinofuranosyl motif of Mycobacterium smegmatis arabinogalactan. J Biol Chem 276 (2001) 48854-48862
7. Alderwick L.J., Seidel M., Sahm H., Besra G.S., and Eggeling L. Identification of a novel arabinofuranosyl transferase (AftA) involved in cell wall arabinan biosynthesis in Mycobacterium tuberculosis. J Biol Chem 281 (2006) 15653-15661. This paper describes the first identification and characterization of a novel arabinofuranosyl transferase that catalyzes the addition of the first key arabinofuranosyl residue to the galactan domain of the cell wall, thus priming the galactan for further elaboration by the arabinofuranosyl transferases. This enzyme is essential for growth in M. tuberculosis, and thus a candidate target for anti-TB drug discovery.
8. Sassetti C.M., Boyd D.H., and Rubin E.J. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48 (2003) 77-84
9. Huang H., Scherman M.S., D'Haeze W., Vereecke D., Holsters M., Crick D.C., and McNeil M.R. Identification and active expression of the Mycobacterium tuberculosis gene encoding 5-phospho-{alpha}-d-ribose-1-diphosphate: decaprenyl-phosphate 5-phosphoribosyltransferase, the first enzyme committed to decaprenylphosphoryl-d-arabinose synthesis. J Biol Chem 280 (2005) 24539-24543
10. Kremer L., Dover L.G., Morehouse C., Hitchin P., Everett M., Morris H.R., Dell A., Brennan P.J., McNeil M.R., Flaherty C., et al. Galactan biosynthesis in Mycobacterium tuberculosis. Identification of a bifunctional UDP-galactofuranosyltransferase. J Biol Chem 276 (2001) 26430-26440
11. Pan F., Jackson M., Ma Y., and McNeil M. Cell wall core galacotfuran synthesis is essential for growth of mycobacteria. J Bacteriol 183 (2001) 3991-3998
12. Li W., Xin Y., McNeil M.R., and Ma Y. rmlB and rmlC genes are essential for growth of mycobacteria. Biochem Biophys Res Comm 342 (2006) 170-178
13. Bloch K. Control mechanisms for fatty acid synthesis in Mycobacterium smegmatis. Adv Enzymol Relat Areas Mol Biol 45 (1977) 1-84
14. Banerjee A., Dubnau E., Quemard A., Balasubramanian V., Um K.S., Wilson T., Collins D., de Lisle G., and Jacobs Jr. W.R. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263 (1994) 227-230
15. Kremer L., Nampoothiri K.M., Lesjean S., Dover L.G., Graham S., Betts J., Brennan P.J., Minnikin D.E., Locht C., and Besra G.S. Biochemical characterization of acyl carrier protein (AcpM) and malonyl-CoA:AcpM transacylase (mtFabD), two major components of Mycobacterium tuberculosis fatty acid synthase II. J Biol Chem 276 (2001) 27967-27974
16. Choi K.H., Kremer L., Besra G.S., and Rock C.O. Identification and substrate specificity of beta -ketoacyl (acyl carrier protein) synthase III (mtFabH) from Mycobacterium tuberculosis. J Biol Chem 275 (2000) 28201-28207
17. Marrakchi H., Ducasse S., Labesse G., Montrozier H., Margeat E., Emorine L., Charpentier X., Daffe M., and Quemard A. MabA (FabG1), a Mycobacterium tuberculosis protein involved in the long-chain fatty acid elongation system FAS-II. Microbiology 148 (2002) 951-960
18. Quemard A., Sacchettini J.C., Dessen A., Vilcheze C., Bittman R., Jacobs Jr. W.R., and Blanchard J.S. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 34 (1995) 8235-8241
19. Kremer L., Douglas J.D., Baulard A.R., Morehouse C., Guy M.R., Alland D., Dover L.G., Lakey J.H., Jacobs Jr. W.R., Brennan P.J., et al. Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J Biol Chem 275 (2000) 16857-16864
20. Musayev F., Sachdeva S., Scarsdale J.N., Reynolds K.A., and Wright H.T. Crystal structure of a substrate complex of Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase III (FabH) with lauroyl-coenzyme A. J Mol Biol 346 (2005) 1313-1321
21. Cohen-Gonsaud M., Ducasse S., Hoh F., Zerbib D., Labesse G., and Quemard A. Crystal structure of MabA from Mycobacterium tuberculosis, a reductase involved in long-chain fatty acid biosynthesis. J Mol Biol 320 (2002) 249-261
22. Rozwarski D.A., Vilcheze C., Sugantino M., Bittman R., and Sacchettini J.C. Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acid substrate. J Biol Chem 274 (1999) 15582-15589
23. Boissier F., Bardou F., Guillet V., Uttenwiler-Joseph S., Daffe M., Quemard A., and Mourey L. Further insight into S-adenosylmethionine-dependent methyltransferases: structural characterization of Hma, an enzyme essential for the biosynthesis of oxygenated mycolic acids in Mycobacterium tuberculosis. J Biol Chem 281 (2006) 4434-4445
24. Pugh C.S., and Borchardt R.T. Effects of S-adenosylhomocysteine analogues on vaccinia viral messenger ribonucleic acid synthesis and methylation. Biochemistry 21 (1982) 1535-1541
25. Portevin D., De Sousa-D'Auria C., Houssin C., Grimaldi C., Chami M., Daffe M., and Guilhot C. A polyketide synthase catalyzes the last condensation step of mycolic acid biosynthesis in mycobacteria and related organisms. Proc Natl Acad Sci USA 101 (2004) 314-319
26. Portevin D., de Sousa-D'Auria C., Montrozier H., Houssin C., Stella A., Laneelle M.A., Bardou F., Guilhot C., and Daffe M. The acyl-AMP ligase FadD32 and AccD4-containing acyl-CoA carboxylase are required for the synthesis of mycolic acids and essential for mycobacterial growth: identification of the carboxylation product and determination of the acyl-CoA carboxylase components. J Biol Chem 280 (2005) 8862-8874. The authors have presented data demonstrating that both FadD32 and AccD4-containing acyl-CoA carboxylase are required for the production of mycolic acids. They also showed that these proteins catalyze the activation of one fatty acid substrate and the carboxylation of the other substrate, respectively, solving the long-debated question of the mechanism involved in the condensation reaction. They have identified AccA3 and AccD5 as subunits of the acyl-CoA carboxylase. Finally, they showed that both the FadD32 and accD4 genes are essential for the survival of mycobacteria, thus validating FadD32 and AccD4 as targets for the development of new antimicrobial drugs against mycobacteria and related microorganisms.
27. Gago G., Kurth D., Diacovich L., Tsai S.C., and Gramajo H. Biochemical and structural characterization of an essential acyl coenzyme A carboxylase from Mycobacterium tuberculosis. J Bacteriol 188 (2006) 477-486. The authors have accomplished heterologous protein expression and purification of the individual subunits and achieved the successful reconstitution of an essential acyl-CoA carboxylase from M. tuberculosis, whose main role appears to be the synthesis of methylmalonyl-CoA. The enzyme complex was reconstituted from the α-biotinylated subunit AccA3, the carboxyltransferase β subunit AccD5, and the ε subunit AccE5 (Rv3281). The kinetic properties of this enzyme showed a clear substrate preference for propionyl-CoA compared with acetyl-CoA (specificity constant fivefold higher), indicating that the main physiological role of this enzyme complex is to generate methylmalonyl-CoA for the biosynthesis of branched-chain fatty acids.
28. Pavelka Jr. M.S., Chen B., Kelley C.L., Collins F.M., and Jacobs Jr. W.R. Vaccine efficacy of a lysine auxotroph of Mycobacterium tuberculosis. Infect Immun 71 (2003) 4190-4192
29. Smith D.A., Parish T., Stoker N.G., and Bancroft G.J. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 69 (2001) 1142-1150
30. Koon N., Squire C.J., and Baker E.N. Crystal structure of LeuA from Mycobacterium tuberculosis, a key enzyme in leucine biosynthesis. Proc Natl Acad Sci USA 101 (2004) 8295-8300
31. Gokulan K., Rupp B., Pavelka Jr. M.S., Jacobs Jr. W.R., and Sacchettini J.C. Crystal structure of Mycobacterium tuberculosis diaminopimelate decarboxylase, an essential enzyme in bacterial lysine biosynthesis. J Biol Chem 278 (2003) 18588-18596
32. Paiva A.M., Vanderwall D.E., Blanchard J.S., Kozarich J.W., Williamson J.M., and Kelly T.M. Inhibitors of dihydrodipicolinate reductase, a key enzyme of the diaminopimelate pathway of Mycobacterium tuberculosis. Biochim Biophys Acta 1545 (2001) 67-77
33. Parish T., and Stoker N.G. The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. Microbiology 148 (2002) 3069-3077
34. Zhang X., Zhang S., Hao F., Lai X., Yu H., Huang Y., and Wang H. Expression, purification and properties of shikimate dehydrogenase from Mycobacterium tuberculosis. J Biochem Mol Biol 38 (2005) 624-631
35. Oliveira J.S., Pinto C.A., Basso L.A., and Santos D.S. Cloning and overexpression in soluble form of functional shikimate kinase and 5-enolpyruvylshikimate 3-phosphate synthase enzymes from Mycobacterium tuberculosis. Protein Expr Purif 22 (2001) 430-435
36. Gourley D.G., Coggins J.R., Isaacs N.W., Moore J.D., Charles I.G., and Hawkins A.R. Crystallization of a type II dehydroquinase from Mycobacterium tuberculosis. J Mol Biol 241 (1994) 488-491
37. Dias M.V., Borges J.C., Ely F., Pereira J.H., Canduri F., Ramos C.H., Frazzon J., Palma M.S., Basso L.A., Santos D.S., and de Azevedo Jr. W.F. Structure of chorismate synthase from Mycobacterium tuberculosis. J Struct Biol 154 (2006) 130-143
38. Gu Y., Reshetnikova L., Li Y., Wu Y., Yan H., Singh S., and Ji X. Crystal structure of shikimate kinase from Mycobacterium tuberculosis reveals the dynamic role of the LID domain in catalysis. J Mol Biol 319 (2002) 779-789
39. Pereira J.H., de Oliveira J.S., Canduri F., Dias M.V., Palma M.S., Basso L.A., Santos D.S., and de Azevedo Jr. W.F. Structure of shikimate kinase from Mycobacterium tuberculosis reveals the binding of shikimic acid. Acta Crystallogr D Biol Crystallogr 60 (2004) 2310-2319
40. Gordhan B.G., Smith D.A., Alderton H., McAdam R.A., Bancroft G.J., and Mizrahi V. Construction and phenotypic characterization of an auxotrophic mutant of Mycobacterium tuberculosis defective in L-arginine biosynthesis. Infect Immun 70 (2002) 3080-3084
41. Errey J.C., and Blanchard J.S. Functional characterization of a novel ArgA from Mycobacterium tuberculosis. J Bacteriol 187 (2005) 3039-3044
42. Chipman D., Barak Z., and Schloss J.V. Biosynthesis of 2-aceto-2-hydroxy acids: acetolactate synthases and acetohydroxyacid synthases. Biochim Biophys Acta 1385 (1998) 401-419
43. Chaleff R.S., and Mauvais C.J. Acetolactate synthase is the site of action of two sulfonylurea herbicides in higher plants. Science 224 (1984) 1443-1445
44. Venos E.S., Knodel M.H., Radford C.L., and Berger B.J. Branched-chain amino acid aminotransferase and methionine formation in Mycobacterium tuberculosis. BMC Microbiol 4 (2004) 39
45. Huovinen P., Sundstrom L., Swedberg G., and Skold O. Trimethoprim and sulfonamide resistance. Antimicrob Agents Chemother 39 (1995) 279-289
46. Gerum A.B., Ulmer J.E., Jacobus D.P., Jensen N.P., Sherman D.R., and Sibley C.H. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother 46 (2002) 3362-3369
47. Li R., Sirawaraporn R., Chitnumsub P., Sirawaraporn W., Wooden J., Athappilly F., Turley S., and Hol W.G. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol 295 (2000) 307-323
48. Sambandamurthy V.K., Wang X., Chen B., Russell R.G., Derrick S., Collins F.M., Morris S.L., and Jacobs Jr. W.R. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 8 (2002) 1171-1174
49. Das S., Kumar P., Bhor V., Surolia A., and Vijayan M. Invariance and variability in bacterial PanK: a study based on the crystal structure of Mycobacterium tuberculosis PanK. Acta Crystallogr D Biol Crystallogr 62 (2006) 628-638
50. Cole S.T., Eiglmeier K., Parkhill J., James K.D., Thomson N.R., Wheeler P.R., Honore N., Garnier T., Churcher C., Harris D., et al. Massive gene decay in the leprosy bacillus. Nature 409 (2001) 1007-1011
51. Morgunova E., Meining W., Illarionov B., Haase I., Jin G., Bacher A., Cushman M., Fischer M., and Ladenstein R. Crystal structure of lumazine synthase from Mycobacterium tuberculosis as a target for rational drug design: binding mode of a new class of purinetrione inhibitors. Biochemistry 44 (2005) 2746-2758. The authors have determined the structure of LS from M. tuberculosis in complex with two purinetrione inhibitors and have studied binding via isothermal titration calorimetry. This forms a basis for structure-based inhibitor design against this novel target.
52. Williams S.J., Senaratne R.H., Mougous J.D., Riley L.W., and Bertozzi C.R. 5′-adenosinephosphosulfate lies at a metabolic branch point in mycobacteria. J Biol Chem 277 (2002) 32606-32615
53. Sassetti C.M., Boyd D.H., and Rubin E.J. Comprehensive identification of conditionally essential genes in mycobacteria. Proc Natl Acad Sci USA 98 (2001) 12712-12717
54. Carroll K.S., Gao H., Chen H., Stout C.D., Leary J.A., and Bertozzi C.R. A conserved mechanism for sulfonucleotide reduction. PLoS Biol 3 (2005) e250
55. Sareen D., Newton G.L., Fahey R.C., and Buchmeier N.A. Mycothiol is essential for growth of Mycobacterium tuberculosis Erdman. J Bacteriol 185 (2003) 6736-6740
56. McCarthy A.A., Peterson N.A., Knijff R., and Baker E.N. Crystal structure of MshB from Mycobacterium tuberculosis, a deacetylase involved in mycothiol biosynthesis. J Mol Biol 335 (2004) 1131-1141
57. Vetting M.W., Roderick S.L., Yu M., and Blanchard J.S. Crystal structure of mycothiol synthase (Rv0819) from Mycobacterium tuberculosis shows structural homology to the GNAT family of N-acetyltransferases. Protein Sci 12 (2003) 1954-1959
58. Eisenreich W., Bacher A., Arigoni D., and Rohdich F. Biosynthesis of isoprenoids via the non-mevalonate pathway. Cell Mol Life Sci 61 (2004) 1401-1426
59. Dawes S.S., Warner D.F., Tsenova L., Timm J., McKinney J.D., Kaplan G., Rubin H., and Mizrahi V. Ribonucleotide reduction in Mycobacterium tuberculosis: function and expression of the class Ib and class II ribonucleotide reductase encoding genes. Infect Immun 71 (2003) 6124-6131
60. Yang F., Lu G., and Rubin H. Isolation of ribonucleotide reductase from Mycobacterium tuberculosis and cloning, expression, and purification of the large subunit. J Bacteriol 176 (1994) 6738-6743
61. Yang F., Curran S.C., Li L.S., Avarbock D., Graf J.D., Chua M.M., Lu G., Salem J., and Rubin H. Characterization of two genes encoding the Mycobacterium tuberculosis ribonucleotide reductase small subunit. J Bacteriol 179 (1997) 6408-6415
62. Elleingand E., Gerez C., Un S., Knupling M., Lu G., Salem J., Rubin H., Sauge-Merle S., Laulhere J.P., and Fontecave M. Reactivity studies of the tyrosyl radical in ribonucleotide reductase from Mycobacterium tuberculosis and Arabidopsis thaliana-comparison with Escherichia coli and mouse. Eur J Biochem 258 (1998) 485-490
63. Liu A., Potsch S., Davydov A., Barra A.L., Rubin H., and Graslund A. The tyrosyl free radical of recombinant ribonucleotide reductase from Mycobacterium tuberculosis is located in a rigid hydrophobic pocket. Biochemistry 37 (1998) 16369-16377
64. Uppsten M., Davis J., Rubin H., and Uhlin U. Crystal structure of the biologically active form of class Ib ribonucleotide reductase small subunit from Mycobacterium tuberculosis. FEBS Lett 569 (2004) 117-122
65. Li de la Sierra I., Munier-Lehmann H., Gilles A.M., Barzu O., and Delarue M. X-ray structure of TMP kinase from Mycobacterium tuberculosis complexed with TMP at 1.95 A resolution. J Mol Biol 311 (2001) 87-100
66. Fioravanti E., Adam V., Munier-Lehmann H., and Bourgeois D. The crystal structure of Mycobacterium tuberculosis thymidylate kinase in complex with 3′-azidodeoxythymidine monophosphate suggests a mechanism for competitive inhibition. Biochemistry 44 (2005) 130-137
67. Gong C., Martins A., Bongiorno P., Glickman M., and Shuman S. Biochemical and genetic analysis of the four DNA ligases of mycobacteria. J Biol Chem 279 (2004) 20594-20606
68. +- and ATP-dependent ligases as evidenced by in vitro assays using T4 ligase and human DNA ligase I. The results can be used as the basis for rational design of novel antibacterial agents.
69. +-dependent DNA ligases are essential in bacteria and are absent from humans, and they have been identified as novel, validated and attractive drug targets. The authors have identified N1, N(n)-bis-(5-deoxy-alpha-D-xylofuranosylated) diamines as a novel class of inhibitors for this enzyme. Assays involving M. tuberculosis LigA, T4 ligase and human DNA ligase I show that these compounds specifically inhibit LigA from M. tuberculosis.
70. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., Gordon S.V., Eiglmeier K., Gas S., Barry III C.E., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 (1998) 537-544
71. Aubry A., Pan X.S., Fisher L.M., Jarlier V., and Cambau E. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 48 (2004) 1281-1288
72. Fleischmann R.D., Alland D., Eisen J.A., Carpenter L., White O., Peterson J., DeBoy R., Dodson R., Gwinn M., Haft D., et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 184 (2002) 5479-5490
73. Munoz-Elias E.J., and McKinney J.D. Mycobacterium tuberculosis isocitrate lyase 1 and are jointly required for in vivo growth and virulence. Nat Med 11 (2005) 638-644. The authors report that the two ICL isoforms in the glyoxylate are jointly required for fatty acid catabolism and virulence in M. tuberculosis. Deletion of both genes resulted in complete impairment of intracellular replication and rapid elimination from the lungs. The feasibility of targeting ICL1 and ICL2 for chemical inhibition was shown using a dual-specific ICL inhibitor, which blocked growth of M. tuberculosis on fatty acids and in macrophages. Glyoxylate cycle inhibitors are thus validated as new drugs for the treatment of tuberculosis.
74. Sharma V., Sharma S., Hoener zu Bentrup K., McKinney J.D., Russell D.G., Jacobs Jr. W.R., and Sacchettini J.C. Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat Struct Biol 7 (2000) 663-668
75. Parish T., and Stoker N.G. glnE is an essential gene in Mycobacterium tuberculosis. J Bacteriol 182 (2000) 5715-5720
76. Zahrt T.C., and Deretic V. An essential two-component signal transduction system in Mycobacterium tuberculosis. J Bacteriol 182 (2000) 3832-3838
77. Rodriguez G.M., Voskuil M.I., Gold B., Schoolnik G.K., and Smith I. ideR, an essential gene in Mycobacterium tuberculosis: role of IdeR in iron-dependent gene expression, iron metabolism, and oxidative stress response. Infect Immun 70 (2002) 3371-3381
78. Boon C., and Dick T. Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J Bacteriol 184 (2002) 6760-6767
79. Meganathan R. Biosynthesis of menaquinone (vitamin K2) and ubiquinone (coenzyme Q): a perspective on enzymatic mechanisms. Vitam Horm 61 (2001) 173-218
80. Perederina A., Svetlov V., Vassylyeva M.N., Tahirov T.H., Yokoyama S., Artsimovitch I., and Vassylyev D.G. Regulation through the secondary channel-structural framework for ppGpp-DksA synergism during transcription. Cell 118 (2004) 297-309
81. Avarbock D., Avarbock A., and Rubin H. Differential regulation of opposing RelMtb activities by the aminoacylation state of a tRNA.ribosome.Mrna.RelMtb complex. Biochemistry 39 (2000) 11640-11648
82. Primm T.P., Andersen S.J., Mizrahi V., Avarbock D., Rubin H., and Barry III C.E. The stringent response of Mycobacterium tuberculosis is required for long-term survival. J Bacteriol 182 (2000) 4889-4898
83. Dahl J.L., Kraus C.N., Boshoff H.I., Doan B., Foley K., Avarbock D., Kaplan G., Mizrahi V., Rubin H., and Barry III C.E. The role of RelMtb-mediated adaptation to stationary phase in longterm persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci USA 100 (2003) 10026-10031
84. Andries K., Verhasselt P., Guillemont J., Gohlmann H.W., Neefs J.M., Winkler H., Van Gestel J., Timmerman P., Zhu M., Lee E., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307 (2005) 223-227. The authors have identified a diarylquinoline, R207910, that inhibits growth of both drug-sensitive and drug-resistant M. tuberculosis in vitro. In mice, R207910 exceeded the bactericidal activities of isoniazid and rifampin by at least 1 log unit. Plasma levels associated with efficacy in mice were well tolerated in healthy human volunteers. Mutants selected in vitro suggest that the drug targets the proton pump of ATP synthase.